What is CUSIP 68235C107?

CUSIP 68235C107 is the security identifier used in SEC filing datasets for OCX - Oncocyte Corporation - Common Shares, No Par Value.

Who owns OCX - Oncocyte Corporation - Common Shares, No Par Value based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

Security Snapshot

Oncocyte Corporation - Common Shares, No Par Value (OCX) Institutional Ownership

CUSIP: 68235C107

13F Institutional Holders and Ownership History from Q4 2015 to Q2 2025

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period

Security type / class: Equity / Common Shares, No Par Value
Symbol: OCX on Nasdaq
Shares outstanding: 28,495,649

13F Shares, Excluding Options vs Price

13F Value, Excluding Options

Total Investors

Key facts

OCX - Oncocyte Corporation - Common Shares, No Par Value is tracked under CUSIP 68235C107.
Latest finished 13F holder period is not available.
2 significant owners is listed from Schedule 13D/13G reporting.

Change

Holder count moved from 1 to 0 between Q1 2025 and Q2 2025.
SEC-reported value moved from $126,921 to $0.

Research use

You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

68235C107

Latest holder period

n/a

13F holders

13D/G owners

CIK / CUSIP context first

OCX full holder history Insight Molecular Diagnostics Inc. SEC filings Insight Molecular Diagnostics Inc. company facts Insight Molecular Diagnostics Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 68235C107:

Q2 2025 (0 holders) Q1 2025 (1 holder) Q4 2024 (1 holder) Q3 2024 (1 holder) Q2 2024 (2 holders) Q1 2024 (2 holders) Q4 2023 (2 holders) Q3 2023 (2 holders) Q2 2023 (45 holders) Q1 2023 (51 holders)

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows

Security

OCX

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
BIO-RAD LABORATORIES, INC.	9.7%		$608,097		2,764,078		BIO-RAD LABORATORIES, INC	10 Feb 2025
SMITH PATRICK W	10%		$4,221,889		1,773,903		Patrick W. Smith	26 Dec 2024

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods

Latest

n/a

Rows shown

1-25 of 39

Period	13F Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2025 Q2	0	$0	-$126,921				0
2025 Q1	44,378	$126,921	-$7,722			$2.86	1
2024 Q4	47,078	$112,046	-$29,215			$2.38	1
2024 Q3	59,353	$169,156	-$3,224,887			$2.85	1
2024 Q2	1,152,395	$3,399,565	+$1,009,560			$2.95	2
2024 Q1	810,171	$2,373,801	-$46,191			$2.93	2
2023 Q4	825,936	$2,049,754	-$20,365			$2.49	2
2023 Q3	833,802	$2,716,547	-$68,395,020		$0	$3.20	2
2023 Q2	91,821,550	$21,118,229	+$8,239,978		$2,323	$0.23	45
2023 Q1	55,657,631	$19,725,177	-$1,788,149			$0.35	51
2022 Q4	60,727,357	$19,486,077	-$2,603,944		$0	$0.32	55
2022 Q3	66,115,361	$48,286,884	-$1,938,715		$18,000	$0.73	55
2022 Q2	68,689,787	$61,801,567	+$12,093,920	$0	$115,000	$0.90	64
2022 Q1	54,297,692	$81,004,102	-$2,234,275	$19,000	$248,000	$1.49	76
2021 Q4	55,309,802	$119,904,059	-$4,932,956	$87,000	$569,000	$2.17	82
2021 Q3	56,556,369	$201,842,971	-$4,273,319	$177,000	$1,191,000	$3.56	91
2021 Q2	56,557,145	$324,629,337	+$10,097,713	$564,000	$1,178,000	$5.74	88
2021 Q1	54,525,746	$282,982,492	+$112,979,747	$735,000	$1,286,000	$5.19	84
2020 Q4	32,820,981	$78,442,746	+$4,663,024	$115,000	$362,000	$2.39	56
2020 Q3	31,284,691	$43,477,422	-$4,537,534		$20,000	$1.39	55
2020 Q2	32,913,612	$62,907,536	+$9,179,739			$1.91	57
2020 Q1	27,664,198	$67,748,452	+$4,418,527			$2.45	52
2019 Q4	25,884,634	$58,219,716	+$15,568,577			$2.25	50
2019 Q3	18,982,051	$39,859,066	+$6,042,313			$2.10	53
2019 Q2	15,958,159	$39,753,182	-$2,942,657			$2.49	48